Tempus AI (TEM) Stock Climbs After First Quarterly Profit and AI Cancer Breakthrough
TLDR
- TEM stock surged over 11% on Friday, trading at $50.95
- New clinical results published in Nature Medicine highlight Tempus’s PRISM2 AI model as a top cancer detection tool
- A short squeeze is likely contributing to the move, with over 30% of the float sold short
- Peer Doximity reported strong earnings, boosting the broader AI-healthcare sector
- Tempus’s planned acquisition of Personalis includes a clause that could kill the deal if TEM falls below $46
Tempus AI (TEM) stock jumped more than 11% on Friday, trading at $50.95 at time of publication, outpacing both the Nasdaq’s 0.86% gain and the Healthcare sector’s 0.3% rise.
The rally was driven by multiple catalysts hitting at once.
Clinical results published in Nature Medicine showed Tempus’s PRISM2 AI model performing as a best-in-class tool for cancer detection and prognosis. That news got investors moving quickly.
With more than 30% of the float sold short, the upward pressure likely turned into a short squeeze, amplifying the move.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
